Fig. 6.

Continuous stimulation of glial hM3Dq receptors with clozapine-n-oxide (CNO) in vivo decreases mouse body weight without decreasing neuronal survival. Schematic representation of the timeline of assays performed on WT littermate and GFAP::hM3Dq mice (A). Weight loss pattern at 4 days after start of treatment with 0.13 mg/ml CNO in water (n = 6 mice; two-way ANOVA with multiple comparisons; ***P = 0.002; ****P < 0.0001; B). In vivo stimulation of GFAP::hM3Dq with CNO does not increase macroscopic damage (C) or decrease neuronal survival (D; n = 6 mice; Student’s t-test). GFAP, glial fibrillary acidic protein; hM3Dq, modified human M3R; M3R, muscarinic type 3 receptor; WT, wild-type.